1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsGrant Application is sponsored by The Styrke Foundation for Rare Disease and Treatment. Provides funding for pre-clinical and clinical therapies for ultra-rare illnesses.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
The Styrke Foundation | Rare Disease Research and Treatment Novel Gene Therapy development The Styrke Foundation for Rare Disease Research and Treatment The Styrke Foundation’s mission is to create a world where children affected by rare genetic haematological diseases can live fulfilling lives without limitations.
We do this by funding initiatives and research projects which aim to accelerate the discovery of new platform-based lentiviral treatments, improve access to care, and empower patients and their families. The DBAS community spoke directly to the FDA. Externally Led Patient-Focused Drug Development Meeting Recap Diamond-Blackfan Anemia Syndrome (DBAS) Patient & Caregiver Experience Survey.
Shape the future of Global DBAS Treatment Influence decision-makers: Your responses go directly to the FDA and researchers evaluating treatments and funding. Strengthen the evidence base: This will be one of the most comprehensive real-world assessments of life with DBAS. Add your voice to the collective: 20 minutes of your time helps build an undeniable case for better treatments.
The survey is completely anonymous. Understanding Rare Diseases Rare diseases, often characterized by their low prevalence and debilitating symptoms, present a unique challenge for both patients and healthcare systems. Despite their collective impact, these conditions frequently face limited funding and research attention.
The Styrke Foundation was established with a singular mission: to improve the lives of individuals affected by rare diseases. Inspired by the unwavering spirit of patients and their families, we have dedicated ourselves to advancing research, developing innovative treatments, and providing essential support.
Join Us in the Fight Against Empower Patients, Transform Lives Your generous donation can make a significant difference in the lives of individuals affected by rare diseases. By supporting The Styrke Foundation, you are investing in a brighter future for countless patients and families. Donate today and join us in the fight against these often overlooked conditions.
To achieve our mission, we focus on the following key aims and objectives: Driving Research : We support groundbreaking research initiatives to uncover the underlying causes of rare diseases and develop innovative therapeutic approaches. Advocacy and Awareness : We raise awareness of rare diseases and advocate for policies that support patients and their families.
Patient Support : We provide essential support services, including counseling, education, and financial assistance, to help patients navigate their journeys. Building Partnerships : We collaborate with leading researchers, healthcare providers, and other organizations to maximize our impact. Hematological diseases represent a significant challenge in medical research.
Despite their prevalence, many of these conditions remain poorly understood and difficult to treat. Our charity is committed to addressing this unmet need by focusing on the development of innovative therapies for hematological disorders. By validating technologies in rare genetic syndrome, we aim to establish a solid foundation for future research and development.
This targeted approach allows us to delve deep into the underlying mechanisms of the disease, identifying potential therapeutic targets and optimizing treatment strategies. From this starting point, we can gradually expand our focus to encompass a broader range of hematological indications, ultimately contributing to the advancement of treatments for these complex and often debilitating disorders.
Platform technologies are essential tools in genetic research and gene editing. They enable precise manipulation of DNA sequences, allowing scientists to target specific genes and make changes. Nucleases like ZFNs, TALENs, and CRISPR-Cas9 are commonly used platform technologies.
Lentiviral & AAVS as it allows for a precise fix, allowing a mechanical solution to a biological problem. These enzymes cut DNA at specific locations, creating breaks that can be repaired with desired changes. The ongoing research Styrke funds aims to address these challenges and ensure safe and effective applications.
How will my donation be used? Styrke's Funds are deployed across 5 key platforms: Research & Development Grants Clinical Trial & Patient Support Grants Regulatory Support Grants Together, we'll find a cure
According to the current listing, eligibility includes: Scientists, research laboratories, institutions, and companies developing gene therapy cures. Confirm the full requirements in the official notice before applying.
Grant Application is funded by The Styrke Foundation for Rare Disease and Treatment. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Anthropic is giving rare-disease researchers and early-stage biotechs up to $50,000 in Claude API credits over six months — not cash, but compute. Here is how the two-track program works, who is eligible, what the credits can and cannot do, and how it fits a fast-growing new category: the compute-as-grant model reshaping how AI-for-science actually gets funded.
Read articleThe Department of Energy's Office of Critical Minerals and Energy Innovation is spending to break America's 95% dependence on foreign rare earths. The strategy is unusual: recover critical materials from the waste streams of coal plants, smelters, and refineries that already exist. Here is the full funding architecture — the $75M just awarded, the $500M battery-materials round, the $1B pipeline behind them — and how an industrial operator should position for what comes next.
Read articleOn June 2, 2026, the Department of Energy's Office of Critical Minerals and Energy Innovation selected two demonstration-scale facilities — Phoenix Tailings (with MIT and the University of Minnesota) for $66 million, and the Colorado School of Mines (with ElementUSA, PNNL, Principal Mineral, and Rare Earth Technologies Inc.) for the balance — under the Rare Earth Elements Demonstration Facility Program. Both projects pull rare earths from industrial waste — red mud at the Gramercy refinery in Louisiana, and a mix of mine and refining tailings elsewhere. Here is what the selections tell researchers, small businesses, and downstream magnet customers about where DOE thinks the chokepoint actually is, and what to do before the next demonstration-scale solicitation opens.
Read article